恩替卡韦治疗代偿期乙型肝炎肝硬化的疗效与安全性观察(1)
 |
| 第1页 |
参见附件。
[摘要] 目的 观察恩替卡韦治疗代偿期乙型肝炎肝硬化患者的疗效与安全性。 方法 60例乙型肝炎肝硬化代偿期患者接受恩替卡韦治疗72周，观察患者生化学指标、病毒学指标和组织学指标的变化情况。 结果 所有患者均没有发展到失代偿期，生化学指标、病毒学指标和组织学指标均有明显改善，差异有统计学意义(P<0.05)。 结论 代偿期乙型肝炎肝硬化患者选用恩替卡韦有良好的疗效及安全性。
[关键词] 肝硬化；恩替卡韦；抗病毒治疗
[中图分类号] R575.2 [文献标识码] A [文章编号] 2095-0616(2012)05-58-02
Clinical observation on compensated cirrhosis patients following chronic hepatitis B virus infection treated with entecavir
GONG Fushan
Pingdingshan Health School, Pingdingshan 467000,China
[Abstract] Objective To determine the clinical therapeutic effect and security of entecavir on compensated cirrhosis patients following chronic hepatitis. Methods Sixty cases of hepatitis B patients with cirrhosis were received entecavir for 72 weeks. Observe the biochemical indicators,virological indicators,histological indicators. Results After anti-viral treatment for 72 weeks,no patients developed into decompensated state,biochemical indicators,virological indicators,and histological indicators had all improved,the differences were statistically significant ......
您现在查看是摘要介绍页，详见PDF附件。